GlassScriptPhysician profile
Jason L Riffe
NPI 1487817698
$6,148.00
in general payments reported to CMS, 2019-2025
39 companies · $1,573 in 2025
The $1,573 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $974 · 2020: $271 · 2021: $69.81 · 2022: $278 · 2023: $1,460 · 2024: $1,523 · 2025: $1,573.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,556.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,555.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,043.39 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $661.68 | 2019-2025 | |
| Abbvie INC. | $569.71 | 2022-2025 | Ubrelvy, Qulipta |
| Bayer Healthcare Pharmaceuticals INC. | $484.37 | 2022-2025 | |
| Lilly USA, LLC | $417.69 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $313.32 | 2019-2024 | Jardiance, Ofev |
| Glaxosmithkline, LLC. | $283.83 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $250.97 | 2019-2023 | Belsomra |
| Exact Sciences Corporation | $217.00 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $184.83 | 2022-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $169.59 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Amgen INC. | $149.08 | 2019-2025 | Otezla, Repatha, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $147.08 | 2023-2025 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $119.03 | 2023-2024 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $118.46 | 2024-2025 | Caplyta |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $106.14 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $86.66 | 2020-2024 | Xarelto, Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $78.97 | 2019-2023 | Trintellix |
| Idorsia Pharmaceuticals US INC | $69.93 | 2023-2024 | Quviviq |
| Novartis Pharmaceuticals Corporation | $64.54 | 2019-2022 | |
| Allergan, INC. | $64.44 | 2019-2022 | |
| Astellas Pharma US INC | $56.47 | 2023-2024 | Veozah, Myrbetriq |
| Sumitomo Pharma America, INC. | $54.66 | 2025 | Gemtesa |
| Aimmune Therapeutics, INC. | $47.49 | 2024-2025 | Zenpep |
| Dexcom, INC. | $40.63 | 2024 | Dexcom G6 Transmitter |
| Radius Health, INC. | $39.12 | 2019 | |
| Lundbeck LLC | $36.83 | 2024 | Rexulti |
| Nalpropion Pharmaceuticals LLC | $36.50 | 2019 | |
| Phathom Pharmaceuticals, INC. | $35.31 | 2025 | Voquezna |
| Biohaven Pharmaceutical Holding Company LTD. | $32.83 | 2022 | |
| Amarin Pharma, INC. | $28.32 | 2019-2020 | |
| Medtronic, INC. | $22.24 | 2024 | Intellis Adaptivestim |
| Pharmacosmos Therapeutics INC. | $20.39 | 2024 | Monoferric |
| Biogen, INC. | $19.72 | 2025 | Skyclarys |
| Dynavax Technologies Corporation | $18.27 | 2024 | Heplisav-B |
| Inspire Medical Systems, INC. | $16.05 | 2025 | Inspire |
| Alk-Abello, INC | $15.62 | 2023 | Odactra, Ragwitek, Grastek |
| Currax Pharmaceuticals LLC | $13.88 | 2024 | Contrave |
| Teva Pharmaceuticals USA, INC. | $12.96 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Riffe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.